5-Ethynyluracil (GW776): Effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model

British Journal of Cancer

Volumn 76, Issue 9, 1997, Pages 1170-1180

  Arellano, M ^a   Malet Martino, M ^a   Martino, R ^a   Spector, T ^b  

^a Université Paul Sabatier   (France)

^b GLAXOSMITHKLINE   (United States)

Author keywords

2 fluoro 3 hydroxypropionic acid; 5 ethynyluracil (GW776); 5 fluorouracil; 19F nuclear magnetic resonance; Fluoroacetate; Isolated perfused rat liver; Modulation of 5 fluorouracil metabolism

Indexed keywords

5 ETHYNYLURACIL; ALPHA FLUORO BETA ALANINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUORINE; FLUOROACETIC ACID; FLUOROURACIL; PROPIONIC ACID DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CARDIOTOXICITY; CATABOLISM; DRUG METABOLISM; LIVER METABOLISM; LIVER PERFUSION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT;

EID: 0030845828     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.529     Document Type: Article

References (39)

1. Anand AJ (1994) Fluorouracil cardiotoxicity. Ann Pharmacother 28: 374-378
2. Arellano M, Malet-Martino M and Martino R (1994) First demonstration that the anticancer drug, 5-fluorouracil, is metabolized in the isolated perfused rat liver into highly cardiotoxic fluoroacetate. Proc Soc Magnetic Resonance 1320.
3. Baccanari DP, Davis ST, Knick VC and Spector T (1993) 5-ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 90: 11064-11068
4. 19F nuclear magnetic resonance. Clin Chem 31: 846-848
5. Brauer RW, Pessotti RL and Pizzolato P (1951) Isolated rat liver preparation. Bile production and other basic properties. Proc Soc Exp Biol Med 78: 174-181
6. Cao S, Rustum YM and Spector T (1994) 5-ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54: 1507-1510
7. Davis ST, Joyner SS, Baccanari DP and Spector T (1994) 5-ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem Pharmacol 48: 233-236
8. Davis ST, Baccanari DP and Spector T (1995) 5-ethynyluracil (5EU, 776C85): effects on thymidylate synthase (TS) inhibition and incorporation of 5-FU into RNA in mice bearing s.c. MOPC-315 tumors. Proc Am Assoc Cancer Res 36: 292
9. Duschinsky R, Walker H, Wojnarowski W, Noack K and Bächtold HP (1973) (+)-α-fluoro-β-alanine (FBAL), the main metabolite of 5-fluorouracil (FU) and its enantiomer. Proc Am Assoc Cancer Res 14: 109
10. Gani D, Hitchcock PB and Young DW (1985) Stereochemistry of catabolism of the DNA base thymine and of the anti-cancer drug 5-fluorouracil. J Chem Soc Perkin Trans 1, 1363-1372
11. Heggie GD, Sommadossi JP, Cross DS, Huster WJ and Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206
12. 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res 48: 1680-1688
13. Khor SP, Lucas S, Hsieh AY, Schilsky R, Burris H, Von Hoff DD and Spector T (1996) 776C85: effect on renal elimination of 5-fluorouracil and uracil in cancer patients. Proc Am Assoc Cancer Res 37: 371
14. Koenig H and Patel A (1970) Biochemical basis for fluorouracil neurotoxicity. Arch Neurol 23: 155-160
15. Lemaire L, Malet-Martino MC, De Forni M, Martino R and Lasserre B (1992) Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 66: 119-127
16. Lemaire L, Malet-Martino MC, Martino R, De Forni M and Lasserre B (1994) The Tris formulation of 5-fluorouracil is more cardiotoxic than the sodium salt formulations. Oncol Rep 1: 173-174
17. Lemaire L, Arellano M, Malet-Martino M and Martino R (1996) A novel metabolite of 5-fluorouracil in humans: 2-fluoro-3-hydroxypropionic acid. Proc Am Assoc Cancer Res 37: 1225
18. Malet-Martino MC and Martino R (1992) Magnetic resonance spectroscopy: a powerful tool for drug metabolism studies. Biochimie 74: 785-800
19. 19F NMR spectrometry evidence for bile acid conjugates of α-fluoro-β-alanine as the main biliary metabolites of antineoplastic fluoropyrimidines in humans. Drug Metab Dispos 16: 78-84
20. Martino R, Lopez A, Malet-Martino MC, Bernadou J and Armand JP (1985) Release of fluoride ion from 5′-deoxy-5-fluorouridine, an antineoplastic fluoropyrimidine, in humans. Drug Metab Dispos 13: 116-118
21. 19F NMR analysis of the carbamate reaction of α-fluoro-β-alanine, the major catabolite of fluoropyrimidines. Application to FBAL carbamate determination in body fluids of patients treated with 5′-deoxy-5-fluorouridine. Drug Metab Dispos 15: 897-904
22. Meldrum GK and Bignell JT (1957) The use of sodium fluoroacetate (compound 1080) for the control of the rabbit in Tasmania. The Aust Vet J 33: 186-196
23. 13. J Biol Chem 235: 433-437
24. Okeda R, Karakama T, Kimura S, Toizumi S, Mitsushima T and Yokoyama Y (1984) Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs. Acta Neuropathol 63: 334-343
25. Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R and Tajima T (1990) Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and α-fluoro-β-alanine. Acta Neuropathol 81: 66-73
26. 19F nuclear magnetic resonance analysis of 5-fluorouracil metabolism in four differently pigmented strains of Nectria haematococca. Appl Environ Microbiol 57: 3605-3612
27. Pattison FLM and Peters RA (1966) Monofluoro aliphatic compounds. In Handbook of Experimental Pharmacology, Smith FA (ed.), pp. 387-458. Springer: New York
28. Porter DJT, Chestnut WG, Merrill BM and Spector T (1992) Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 267: 5236-5242
29. Porter DJT, Harrington JA, Almond MR, Chestnut WG, Tanoury G and Spector T (1995) Enzymatic elimination of fluoride from α-fluoro-β-alanine. Biochem Pharmacol 50: 1475-1484
30. Sabouraud A, Redureau M, Gires P, Martinet M and Scherrmann JM (1993) Effect of colchicine-specific Fab fragments on the hepatic clearance of colchicine. Drug Metab Dispos 21: 997-1002
31. Spector T, Harrington JA and Porter DJT (1993) 5-ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46: 2243-2248
32. Spector T, Porter DJT, Nelson DJ, Baccanari DP, Davis ST, Almond MR, Khor SP, Amyx H, Cao S and Rustum YM (1994) 5-ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil. Drugs Future 19: 565-571
33. Sugano T, Suda K, Shimada M and Oshino N (1978) Biochemical and ultrastructural evaluation of isolated rat liver systems perfused with a hemoglobin-free medium. J Biochem 83: 995-1007
34. Sweeny DJ, Barnes S and Diasio RB (1988) Formation of conjugates of 2-fluoro-beta-alanine and bile acids during the metabolism of 5-fluorouracil and 5-fluoro-2-deoxyuridine in the isolated perfused rat liver. Cancer Res 48: 2010-2014
35. Van Dyke RW, Gollan JL and Scharschmidt BF (1983) Oxygen consumption by rat liver: effects of taurocholate and sulfobromophthalein transport, glucagon, and cation substitution. Am J Physiol 244: G523-G531
36. Wain WH and Staatz WD (1973) Rales of synthesis of ribosomal protein and total ribonucleic acid through the cell cycle of the fission yeast Schizosaccharomyces pombe. Exp Cell Res 81: 269-278
37. Yeh KH and Cheng AL (1994) Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid. J Formos Med Assoc 93: 721-723
38. Zhang R, Soong SJ, Liu T, Barnes E and Diasio RB (1992) Pharmacokinetics and tissue distribution of 2-fluoro-β-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil. Drug Metab Dispos 20: 113-119
39. Zhang R, Liu T, Soong SJ and Diasio RB (1993) A mathematical model of the kinetics and tissue distribution of 2-fluoro-β-alanine, the major catabolite of 5-fluorouracil. Biochem Pharmacol 45: 2063-2069